Partner Investment Management L.P. purchased a new stake in Inogen Inc (NASDAQ:INGN) in the third quarter, HoldingsChannel.com reports. The firm purchased 1,856 shares of the medical technology company’s stock, valued at approximately $453,000.

Several other institutional investors also recently modified their holdings of the stock. Aperio Group LLC grew its holdings in Inogen by 5.7% during the 2nd quarter. Aperio Group LLC now owns 11,915 shares of the medical technology company’s stock worth $2,220,000 after acquiring an additional 638 shares during the period. Raymond James Financial Services Advisors Inc. acquired a new stake in Inogen during the 2nd quarter worth $216,000. First Trust Advisors LP grew its holdings in Inogen by 13.5% during the 2nd quarter. First Trust Advisors LP now owns 25,296 shares of the medical technology company’s stock worth $4,713,000 after acquiring an additional 3,003 shares during the period. Jennison Associates LLC grew its holdings in Inogen by 186.2% during the 2nd quarter. Jennison Associates LLC now owns 119,570 shares of the medical technology company’s stock worth $22,279,000 after acquiring an additional 77,791 shares during the period. Finally, State of Wisconsin Investment Board grew its holdings in Inogen by 79.4% during the 2nd quarter. State of Wisconsin Investment Board now owns 40,000 shares of the medical technology company’s stock worth $7,453,000 after acquiring an additional 17,700 shares during the period. 98.65% of the stock is owned by institutional investors and hedge funds.

A number of analysts have commented on INGN shares. BidaskClub lowered shares of Inogen from a “strong-buy” rating to a “buy” rating in a report on Thursday, September 20th. Needham & Company LLC reaffirmed a “buy” rating and set a $280.00 target price (down previously from $296.00) on shares of Inogen in a report on Wednesday, November 7th. Zacks Investment Research raised shares of Inogen from a “hold” rating to a “buy” rating and set a $290.00 target price for the company in a report on Thursday, September 27th. Piper Jaffray Companies lifted their target price on shares of Inogen from $245.00 to $290.00 and gave the stock an “overweight” rating in a report on Wednesday, September 12th. Finally, Stifel Nicolaus set a $258.00 target price on shares of Inogen and gave the stock a “buy” rating in a report on Tuesday, August 21st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $244.67.

In other news, EVP Brenton Taylor sold 5,000 shares of Inogen stock in a transaction on Monday, October 1st. The shares were sold at an average price of $244.77, for a total transaction of $1,223,850.00. Following the transaction, the executive vice president now directly owns 41,297 shares of the company’s stock, valued at $10,108,266.69. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Raymond Huggenberger sold 10,500 shares of Inogen stock in a transaction on Friday, September 14th. The stock was sold at an average price of $282.57, for a total transaction of $2,966,985.00. Following the transaction, the director now directly owns 8,797 shares in the company, valued at $2,485,768.29. The disclosure for this sale can be found here. Over the last three months, insiders have sold 32,000 shares of company stock worth $7,580,605. Insiders own 5.29% of the company’s stock.

Shares of NASDAQ INGN opened at $140.94 on Thursday. The firm has a market cap of $3.07 billion, a PE ratio of 107.59, a PEG ratio of 2.79 and a beta of 1.49. Inogen Inc has a twelve month low of $112.78 and a twelve month high of $287.79.

Inogen (NASDAQ:INGN) last announced its quarterly earnings results on Tuesday, November 6th. The medical technology company reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of $0.52 by $0.21. The company had revenue of $95.29 million for the quarter, compared to analysts’ expectations of $90.94 million. Inogen had a net margin of 12.28% and a return on equity of 18.91%. The business’s quarterly revenue was up 38.0% compared to the same quarter last year. During the same period last year, the firm posted $0.33 earnings per share. On average, research analysts anticipate that Inogen Inc will post 2.1 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Partner Investment Management L.P. Purchases New Holdings in Inogen Inc (INGN)” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://www.thecerbatgem.com/2018/12/06/partner-investment-management-l-p-purchases-new-holdings-in-inogen-inc-ingn.html.

Inogen Profile

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Featured Story: Technical Analysis of Stocks, How Can It Help

Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen Inc (NASDAQ:INGN).

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.